WHO, Dept. Essential Drugs and Medicines Policy Measuring use of medicines: progress in the last decade Kathleen Holloway and Verica Ivanovska Dept. Essential.

Slides:



Advertisements
Similar presentations
Usage statistics in context - panel discussion on understanding usage, measuring success Peter Shepherd Project Director COUNTER AAP/PSP 9 February 2005.
Advertisements

Chronic disease self management – a systematic review of proactive telephone applications Carly Muller Dean Schillinger Division of General Internal Medicine.
Copyright © Healthcare Quality Quest, Proposed standards for a national clinical audit — How we got involved and what we have learned.
Promoting Rational Use of Injections within National Medicine Policies World Health Organisation Dept. Essential Drugs and Medicines Policy Safe Injection.
Doug Altman Centre for Statistics in Medicine, Oxford, UK
ECONOMIC ASSESSMENT OF IMPLEMENTATION TREATMENT GUIDELINES OF HYPERTENSION IN OUT-PATIENT PRACTICE Kulmagambetov IR Karaganda State Medical Academy, Kazakhstan.
Generating Information for Medicines Benefit Management: A Systems Framework Dennis Ross-Degnan, ScD Harvard Medical School and Harvard Pilgrim Health.
2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.
Drug and Therapeutics Committee Session 7A. Identifying Problems with Medicine Use: Indicator Studies.
EDM STRATEGY FOR WORKING WITH COUNTRIES-TANZANIA Rose Shija EDM NPO TANZANIA.
Generating evidence for change: Implementing the post-ICIUM research agenda Dennis Ross-Degnan, ScD Harvard Medical School and Harvard Pilgrim Health Care.
The rise and fall of supervision in a project designed to strengthen supervision on the Integrated Management of Childhood Illness (IMCI) strategy in Benin*
TRENDS AND CONSUMERISM IN HEALTH CARE Important Attributes Of Quality Health Care: Consumer Perspectives.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
Impact on prescribing patterns of a fee per drug unit versus a fee per drug item Kathleen Holloway 1, Karkee SB 2, Tamang AL 2, Gurung YB 2, Pradhan R.
WHO local pilot projects to contain AMR ICIUM 2004 K.A.Holloway and T.L.Sorensen Essential Drugs and Medicines Policy WHO Geneva.
Impact of a public education program on promoting rational use of medicines: a household survey in south district of Tehran, Darbooy SH, Hosseini.
Ministry of Health People’s Republic of ChinaPage 1 中华人民共和国 卫生部 Promoting Rational Antibiotic Prophylaxis in Clean Surgeries in China, Zheng, Yingdong;
CINAHL Nursing Guide –Nearly 3,600 Evidence-based lessons on procedures, diseases and conditions, legal cases and drugs 2,200+ care sheets & lessons 700+
WHO Level II Facility Surveys Douglas Ball Independent consultant, UK.
1 What are Monitoring and Evaluation? How do we think about M&E in the context of the LAM Project?
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
Unit 10. Monitoring and evaluation
دکتر خلیلی 1. Lucid the way to “ Research” And Follow an “ Evidence Based Medicine”
United Nations Economic Commission for Europe Statistical Division Getting the Facts Right: Metadata for MDG and other indicators UNECE Baku, Azerbaijan,
Problem Statement: In Kenya, despite the development of national standard treatment guidelines (STGs) for the management of acute respiratory infections.
Determining Acceptable Waiting Times for the Surgical Treatment of Solid Organ Malignancies - A Systematic Review CIHR Grant: Toward Canadian Benchmarks.
Health Promotion as a Quality issue
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
Seminar THREE The Patient Record:
Promoting Drug and Therapeutics Committees in the Developing World
NICE - in evidence based commissioning Gateshead Council Gillian Mathews, Implementation Consultant - North 9 September 2011.
Drug Prescribing Practices in Children under 5 with Acute Respiratory Infection in Family Group Practices in Central Kazakhstan Nurgozhin Talgat ZdravPlus/USAID.
Do Village Revolving Funds Improve Access and Rational Use of Drugs in Laos? Bigdeli M 1 Ketsouvannasane B 2 Shuey DA 1 1.WHO, Laos 2.Ministry of Health,
Determinants of Rational Use of Medicines Dr A K Sharma Prof & Head Dept of Pharmacology AFMC, Pune.
A BASELINE SURVEY OF THE PHARMACEUTICAL SECTOR IN TANZANIA
Abstract Impact of the Essential Drugs Programme at the Primary Health Care Level in South Africa Hela M, Zeeman H, Department of Health South Africa;
Table of Contents – Part B HINARI Resources –Clinical Evidence –Cochrane Library –EBM Guidelines –Essential Evidence Plus –HINARI EBM Journals.
Authors: Lates JA, Shiyandja NN Funding Institution: Ministry of Health and Social Services, Namibia Title: Third National Survey on the Use of Drugs in.
A COMPARISON OF PRESCRIBING PRACTICES BETWEEN PUBLIC AND PRIVATE SECTOR PHYSICIANS IN UGANDA Obua C, Ogwal-Okeng JW, WaakoP, Aupont O, Ross-Degnan D International.
Finding, Evaluating, and Presenting Evidence Sharon E. Lock, PhD, ARNP NUR 603 Spring, 2001.
WHO PRESCRIBING INDICATORS (1991 – 1995) TRENDS AND PERSPECTIVES IN AN OUTPATIENT HEALTH CARE FACILITY IN BENIN CITY, NIGERIA. 1 Isah AO, 2 Isah EC, 3.
Indicators for monitoring and assessing pharmaceutical situation in countries Dr. Edelisa D. Carandang Drug Action Program (DAP) Essential Drugs and Medicines.
Background: Tomson G 1, Kronvall G 2, Chuc NTK 3, Binh NT 4, Chalker J 5, Falkenberg T 1. 1 Div. International Health (IHCAR), Dep. Public Health Sciencies,
Medicines use in primary care in developing and transitional countries Results from studies reported between Kathleen Holloway, Verica Ivanovska,
MONITORING THE PHARMACEUTICAL SECTOR IN A DEVELOPING COUNTRY - THE GHANA EXAMPLE Gyansa-Lutterodt M. 1,7, Andrews E 2, Arhinful D 3,7, Addo-Atuah J 4,7,
RECENT ADVANCES IN PROVISION OF PRIMARY HEALTH CARE BY MISSION ORGANIZATIONS THE EFFECT OF AN EDUCATIONAL INTERVENTION ON USE OF ANTIBIOTICS IN THE TREATMENT.
Overview of National Center for Health Statistics (NCHS) Data Systems Mary Burgess
Learning About Drug Use1 An Overview of the Process of Changing Drug Use 1. EXAMINE Measure Existing Practices (Descriptive Quantitative Studies) 2. DIAGNOSE.
How the Clinical Effectiveness Team can help you to audit your Prescribing Practice Jude Scott Clinical Governance & Risk Management Unit Clinical Effectiveness.
Care Quality Commission (CQC) Registration. Background The Care Quality Commission (CQC) is the health and social care regulator for England. From 1 April.
Heart Failure Audit Dr Jenny Welstand Lead Nurse Heart Failure Service Wrexham Maelor Hospital Acknowledgements: North Wales Cardiac Network Dr Richard.
Medicines use in children under 5 years primary care in developing and transitional countries Results from studies reported between Kathleen.
DATA FOR EVIDENCE-BASED POLICY MAKING Dr. Tara Vishwanath, World Bank.
ABSTRACT THE IMPACT OF CONTINUOUS MEDICAL EDUCATION ON PRESCRIBING HABITS IN MISSION HOSPITALS IN KENYA By John Kiambuthi Mission for essential drugs and.
Prescribing indicators Total number of drugs/encounters (n)
ABSTRACT THE IMPACT OF CONTINUOUS MEDICAL EDUCATION ON PRESCRIBING
Distraction Techniques during pediatric medical procedures
Patient Medical Records
Patterns of asthma medications prescriptions among adult patients in the chest and accident and emergency units of a tertiary health care facility in Uganda.
Trap B and Hansen EH Euro Health Group, Denmark &
Impact of a public education program on promoting rational use of medicines:
Managerial and Regulatory Strategies to Improve Drug Use
Essential Drugs and Medicines Policy
Toktobaeva B, Karymbaeva S Drug Information Centre Kyrgyzstan
Essential Drugs and Medicines Policy
monitoring & evaluation THD Unit, Stop TB department WHO Geneva
Impact on prescribing patterns of a fee per drug unit versus a fee per drug item Kathleen Holloway1, Karkee SB2, Tamang AL2, Gurung YB2, Pradhan R2, Reeves.
Syhakhang L, Stenson B, Stålsby LC, Eriksson B, Tomson G
International Conference on Improving Use of Medicines
Presentation transcript:

WHO, Dept. Essential Drugs and Medicines Policy Measuring use of medicines: progress in the last decade Kathleen Holloway and Verica Ivanovska Dept. Essential Drugs and Medicines Policy WHO Geneva ICIUM, March 30 – April 2, 2004

WHO, Dept. Essential Drugs and Medicines Policy2 WHO database of all drug use surveys done in developing countries Objectives To provide an overview of drug use –existing drug use patterns in primary health care settings in developing and transitional countries over time To identify effective interventions and trends –impact of different types of interventions on improving the use of drugs To provide evidence for advocacy, planning –tool for routine monitoring nationally & internationally

WHO, Dept. Essential Drugs and Medicines Policy3 Criteria for inclusion of study in database Quantitative data on drug use Descriptive and intervention studies Developing and transitional countries Primary health care patients –primary health care clinics –hospital general & paeds non-specialist outpatients –pharmacies, drug sellers and households Articles in English, French, Spanish, Russian Reported/published during

WHO, Dept. Essential Drugs and Medicines Policy4 Methods Search strategy –INRUD bibliography & WHO archives Retrieval strategy –WHO library resources Database format –Access, compatible with other WHO databases Data entry –one record per published survey divided again by country, health facility type/level, prescriber type Data analysis –Time series & comparisons between sectors, regions, etc –Export into excel and later into statistical packages

WHO, Dept. Essential Drugs and Medicines Policy5 Design of the database 1st section on demographic detail –country, year of survey, publication reference, healthcare setting, prescriber/dispenser type, patient/disease type 2nd section on types of interventions –provider education, printed materials, supervision & audit, economic strategies, regulation, essential drug programs 3rd section on methodological details –study design, sample sizes (prescriptions, facilities, patients), data collection 4th section on drug use indicators –WHO/INRUD indicators, IMCI and specific disease indicators, mortality rates, additional indicators

WHO, Dept. Essential Drugs and Medicines Policy6 Current status INRUD bibliography –3080 articles screened –207 (7%) articles met the inclusion criteria WHO/Essential Drugs & Medicines archives –67 unpublished articles/reports entered WHO/Child Adolescent Health archives –71 unpublished articles/reports entered 441 data records entered in the database –about half surveys done to evaluate an intervention

WHO, Dept. Essential Drugs and Medicines Policy7 Reliability of search strategy Comparing retrieval of intervention studies of good study design between ICIUM1997 review and WHO database WHO database contained 11 out of 17 articles used for 1997 ICIUM review i.e. 6 articles missing –3 articles with non-relevant outcomes –3 articles with relevant outcomes Unpublished study identified in INRUD bibliography but not retrievable (1 study) Not in INRUD bibliography (1 study) – subsequently retrieved and entered Missed article (1 study) – subsequently retrieved and entered

WHO, Dept. Essential Drugs and Medicines Policy8 Methodological challenges Some surveys published in more than one article, sometimes with inconsistent results Standard indicators often not used Missing data –survey year, facility type, facility level, prescriber type Data sometimes difficult to classify –indicators sometimes poorly described –drug use reported for a mix of facility / prescriber type –description of study design in article descriptions not consistent with database definitions time series stated but 4 data points not described “retrospective” interviews/observation described

WHO, Dept. Essential Drugs and Medicines Policy9 Problems of classifying data Surveys may be divided on the basis of facility or prescriber, but... –If the prescribers include MDs, nurses and paramedics, what is the prescriber type? –If there are 20 PHC facilities and 2 hospitals, what is the facility level? Standard indicators used in database but outcomes maybe poorly described, so... –Does “% antibiotic use” mean “% patients treated with antibiotics” or the “% drugs used that were antibiotics”?

WHO, Dept. Essential Drugs and Medicines Policy10 Rules: survey description Surveys not divided on basis of disease Judging a prescriber as “self” can only be done from a household survey Facility level refers to the source of drug use data (not intervention target group or place) Prescriber type refers to the main prescriber in the study irrespective of whether an intervention is aimed at the prescriber or there are any prescribing indicators reported

WHO, Dept. Essential Drugs and Medicines Policy11 Rules: survey methodology Interviews or observation can only be done prospectively Time series study design has more than 4 data points No. health facilities or no. patients per health facility are based on the lowest number during any one measurement or for any time period for any outcome variable Total no. patients is based on all patients in the study for all time periods of measurement

WHO, Dept. Essential Drugs and Medicines Policy12 Rules: outcome variables If an outcome is reported by individual facilities and patients, calculating an overall result should be done by averaging across facilities not patients. Prescription-only-medicines (POM) –POM are either defined as such in the article or are otherwise considered to be injections and antibiotics. –Availability of POM over the counter has a numerator that is the number of patients that got POM without a prescription, and a denominator that is the total number of patients given POM; this cannot be judged from a simulated patient survey

WHO, Dept. Essential Drugs and Medicines Policy13 Facility types

WHO, Dept. Essential Drugs and Medicines Policy14 Facility level

WHO, Dept. Essential Drugs and Medicines Policy15 Prescriber types

WHO, Dept. Essential Drugs and Medicines Policy16 Intervention types 844 interventions in 204 study sites

WHO, Dept. Essential Drugs and Medicines Policy17 WHO/INRUD Prescribing Indicators

WHO, Dept. Essential Drugs and Medicines Policy18 10-year trends in antibiotic & injection use N= 9 per year (on average)

WHO, Dept. Essential Drugs and Medicines Policy19 WHO/INRUD patient care indicators

WHO, Dept. Essential Drugs and Medicines Policy20 WHO/INRUD facility indicators

WHO, Dept. Essential Drugs and Medicines Policy21 Public/private prescribing for all years

WHO, Dept. Essential Drugs and Medicines Policy22 Public / private patient care for all years

WHO, Dept. Essential Drugs and Medicines Policy23 Prescribing by prescriber type for all years

WHO, Dept. Essential Drugs and Medicines Policy24 ARI treatment in last decade

WHO, Dept. Essential Drugs and Medicines Policy25 ARI treatment by prescriber %

WHO, Dept. Essential Drugs and Medicines Policy26 ARI treatment by region for all years

WHO, Dept. Essential Drugs and Medicines Policy27 Diarrhoea treatment in last decade

WHO, Dept. Essential Drugs and Medicines Policy28 Public/private diarrhoea treatment for all years

WHO, Dept. Essential Drugs and Medicines Policy29 Diarrhoea treatment by region for all years %

WHO, Dept. Essential Drugs and Medicines Policy30 Future areas of work Inclusion of hospital inpatient and specialist studies, self medication, patients’ compliance, diagnostic accuracy Link with other WHO databases –National Drug Policy, Burden of Diseases, Safe Injection Global Network Internet availability Integrate into routine monitoring and use the data for evidence-based planning & advocacy

WHO, Dept. Essential Drugs and Medicines Policy31 Conclusions Uses of WHO database of drug use surveys track drug use over time and between countries –plan future strategy & evaluate past strategy –identify effective interventions and policies –routine monitoring and evidence-based advocacy Initial findings over the last decade Few surveys and even fewer interventions done, mostly in the public sector Irrational drug use remains a very serious problem Increased antibiotic use and decreased injection use Prescribing often better in public than private sectors

WHO, Dept. Essential Drugs and Medicines Policy32 Thank you Prof. Dennis Ross-Degnan –For constant support and advice throughout with regard to database design and analysis Jorge Hetzke –For help designing and maintaining the database Richard Laing and Hans Hogerzeil –Advice and support All authors around the world –For clarifying their studies for us